Advancing target validation and phenotypic drug discovery strategies through combined high content analysis, intravital imaging and reverse phase protein array technology

Wed3  Sep11:00am(30 mins)
Charter 1
 Neil Carragher


Limited understanding of drug mechanism-of-action and pharmacological resistance contributes to poor efficacy and attrition at later stages of drug discovery and development. We demonstrate how complex high content assays, intravital imaging and Reverse Phase Protein Microarray (RPPA) technologies can combine to enable a robust and unbiased approach to profiling compound mechanism-of-action and validating target hypothesis within disease relevant in vitro and in vivo settings.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021